The following are selected life science industry transactions and financings that were executed by senior members of the Firm.

  • Bayer AG: Acted as advisor to Bayer Corporation in the sale of ChemDesign Corporation, a fine chemical company, to   Chestnut Investments LLC.
  • Caliper Life Sciences: Acted as advisor to Caliper Life Sciences, the leading microfluidics company, in its acquisition of NovaScreen, a life science services company.
  • Chirex: Co-managed the $87 million IPO of this pharmaceutical and intermediates company.
  • Genzyme Corporation: Acted as advisor to Genzyme Corporation in the sale of its Genzyme Pharmaceutical Ingredients Business in    Switzerland, to International Chemical Investors Group (ICIG).
  • Insignis Therapeutics: Completed a strategy project to devise and refine the business and financial strategy of Insignis.
  • Insignis Therapeutics: Completed second round of financing via a private placement of equity for this producer of an EpiPen alternative for the treatment of anaphylaxis
  • Lipella Pharmaceuticals: Completed a corporate business and regulatory strategy review, including assessing strategic/financial alternatives
  • LKC Technologies: Acted as placement agent for private placement of securities for this retinal diagnostics company.
  • ÖMV:  Acted as advisor in the sale of ÖMV’s fine chemical division, Chemie Linz, located in Austria, to DSM for 2.2    billion schillings
  • Paratek Pharmaceuticals: Acted as advisor to Paratek with regard to a review of its strategic, regulatory and financial alternatives
  • Perkin-Elmer Corporation: Acted as advisor to the Perkin-Elmer Corporation in the sale of PerSeptive Biosystems GmbH-Hamburg to a subsidiary of SKW Trostberg AG.
  • Phyto-Source L.P.: Advised the shareholders of Phyto-Source, a leading supplier of phytosterols, in the sale of the business to   Cognis.
  • SilverMill: Acted as advisor to SilverMill in its acquisition of Cedarlane Laboratories
  • Synthon Chiragenics: Acted as advisor to Synthon Chiragenics in the sale of its Fine Chemicals business and the license of certain technology rights to Avecia Ltd.